Alzheimer’s drugs show no meaningful benefit, major review finds
Alzheimer’s drugs show no meaningful benefit, major review finds
A major review questions the clinical impact of lecanemab and donanemab, fueling UK licensing debates.
A recent clinical review examining anti-amyloid therapies, including lecanemab and donanemab, concludes that the observable effects on patients are small, often described as trivial. The findings add fuel to ongoing discussions about whether these medications truly change the course of Alzheimer’s disease or simply move the needle in trial measurements.
The report notes that two anti-amyloid drugs are licensed in the UK, but critics say the analysis lumps older, unsuccessful drugs with the two recently approved treatments, risking a skewed picture of their overall value. This has sparked a broader debate about how best to evaluate new therapies in a field where evidence is complex and long-term outcomes remain uncertain.
Advocates for the drugs say even small cognitive shifts could be meaningful for some individuals and families, and real-world data may reveal benefits not fully captured in trials. They argue that patients facing progressive decline may welcome any delay in symptoms or preservation of daily function, even if gains are modest on standardized tests.
Health systems are weighing cost, access, and ongoing monitoring against uncertain long-term impact. Policymakers and clinicians are balancing patient needs with the drugs’ price tags, potential side effects, and the possibility that benefits vary widely among patients. This tension highlights the importance of personalized discussions between physicians and families about expectations and choices.
Experts are calling for more transparent data, longer follow-up, and careful patient selection as more real-world experience accumulates. Until then, the debate over the true value of these anti-amyloid therapies in routine care is likely to continue, shaping how Alzheimer’s treatment is pursued in the years ahead.
